4D Molecular Therapeutics (NASDAQ:FDMT) Coverage Initiated at B. Riley Financial

Investment analysts at B. Riley Financial assumed coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note issued on Friday. The brokerage set a “buy” rating and a $37.00 price target on the stock. B. Riley Financial’s price objective suggests a potential upside of 267.43% from the company’s current price.

Several other equities research analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday. Finally, The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.67.

4D Molecular Therapeutics Trading Up 4.8%

Shares of NASDAQ FDMT opened at $10.07 on Friday. 4D Molecular Therapeutics has a 12-month low of $4.30 and a 12-month high of $14.00. The company has a market cap of $526.42 million, a PE ratio of -3.92 and a beta of 2.70. The stock has a 50 day simple moving average of $10.55 and a 200-day simple moving average of $9.64.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Sell-side analysts forecast that 4D Molecular Therapeutics will post -3.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider David Kirn sold 15,725 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $12.03, for a total value of $189,171.75. Following the transaction, the insider owned 884,152 shares in the company, valued at approximately $10,636,348.56. This represents a 1.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares of the company’s stock, valued at approximately $103,404. The trade was a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 184,811 shares of company stock valued at $2,075,906 over the last three months. 7.90% of the stock is owned by insiders.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth about $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the third quarter worth approximately $41,000. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics in the first quarter worth approximately $46,000. Daiwa Securities Group Inc. raised its position in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC bought a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $48,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.